Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Baba PD Inusa, MD, Adlette Inati, MD, Philip Maes, MD, Jessie Githanga, MBChB, MMed, Miguel R. Abboud, MD, Maurizio Miano, Elena Cela, Videlis Nduba, Mohammad Niazi, Magnus Åstrand, Kevin Persson, Anders Rikard Berggren, MD PhD, Glenn Carlson, MD

Blood (2019) 134 (Supplement_1): 1005.

https://doi.org/10.1182/blood-2019-129855

Published: 2019

Journal Articles

Pharmacokinetics, Pharmacodynamics and Safety of Ticagrelor in Children with Sickle Cell Disease: Results of a Two-Part Phase 2 Study

Lewis L Hsu, MD PhD, S Sarnaik, S Williams, C Amilon, M Rensfeldt, A Berggren

Blood (2017) 130 (Supplement 1): 2251.

https://doi.org/10.1182/blood.V130.Suppl_1.2251.2251

Published: 2017

Journal Articles

Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies

John Chapin, Stephen Eyler, Richard Smith, Han-Mou Tsai, Jeffrey Laurence

Blood (2013) 121 (19): 4012–4013.

https://doi.org/10.1182/blood-2013-03-487694

Published: 2013

Journal Articles

The Alternate Complement Pathway in Thrombotic Thrombocytopenic Purpura

John C. Chapin, MD, Katrina Piskorski, Stephen J Eyler, MD, Richard J. H. Smith, MD, Jeffrey Laurence, MD

Blood (2012) 120 (21): 3342.

https://doi.org/10.1182/blood.V120.21.3342.3342

Published: 2012

Journal Articles

Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.

Charles Bennett, MD, PhD, MPP, Masanori Matsumoto, MD, Peter Georgantopoulos, MPH, AM, Sony Jacob, MD, Brianne L Dunn, PharmD, Zaina Parvez Qureshi, PhD, MPH, Nicholas Bandarenko, III, MD, Hau C. Kwaan, MD, PhD, Jeffrey Winters, MD, Ravindra Sarode, MD, Joseph E Kiss, MD, Constance Danielson, MD, PhD, Thomas L. Ortel, MD, PhD, Thomas Raife, MD, William F Clark, MD, Gail Rock, PhD, MD, FRCP, X. Long Zheng, MD, PhD, Dennis Raisch, Ph.D., M.S., R.Ph., Yoshihiro Fujimura, MD, PhD

Blood (2012) 120 (21): 2203.

https://doi.org/10.1182/blood.V120.21.2203.2203

Published: 2012

Journal Articles

Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience

Grace Kam, MBBS, MRCP, Richard Yiu, Ai Leen Ang, MBBS, MMed, (Internal, Medicine), Yvonne SM Loh, MBBS, MRCP, Yeh Ching Linn, MBBS, Lai Heng Lee, MBBS, MMed, Yeow Tee Goh, MBBS, MMed, Gee Chuan Wong, MBBS, MRCP, FRCP

Blood (2012) 120 (21): 5060.

https://doi.org/10.1182/blood.V120.21.5060.5060

Published: 2012

Journal Articles

Anti-ADAMTS13 Inhibitor Boosting During Plasma Exchange Therapy Often Causes an Intractable Acquired Idiopathic TTP

Ayami Isonishi, BS, Masanori Matsumoto, MD, PhD, Friedrich Scheiflinger, PhD, Barbara Plaimauer, PhD, Charles Bennett, MD, PhD, MPP, Yoshihiro Fujimura, MD, PhD

Blood (2012) 120 (21): 1086.

https://doi.org/10.1182/blood.V120.21.1086.1086

Published: 2012

Journal Articles

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty Year Review

Zaina Parvez Qureshi, PhD, MPH, John Armstrong, PhD, Charles Bennett, MD, PhD, MPP

Blood (2011) 118 (21): 2226.

https://doi.org/10.1182/blood.V118.21.2226.2226

Published: 2011

Journal Articles

Translating Research Into Policy: A Review of Pharmacovigilance Efforts From the Southern Network On Adverse Reactions (SONAR) Group

Charles Bennett, MD, PhD, MPP, Leann Norris, PharmD, Zaina Parvez Qureshi, PhD, MPH, April Miller, PharmD, Brandon Bookstaver, PharmD, BCPS (AQ-ID), AAHIVE, Donald Mattison, M.D., CAPT, USPHS

Blood (2011) 118 (21): 4756.

https://doi.org/10.1182/blood.V118.21.4756.4756

Published: 2011

Journal Articles

Finishing the Picture: Clopidogrel Is Indeed the Most Common Drug Associated with Thrombotic Thrombocytopenic Purpura (TTP) In FDA Databases: Its Mechanism, Laboratory Findings, Clinical Features, and Epidemiology Differ From That Associated with Ticlopidine

Charles Bennett, MD, PhD, MPP, Zaina Qureshi, PhD, MPH

Blood (2010) 116 (21): 1527.

https://doi.org/10.1182/blood.V116.21.1527.1527

Published: 2010

Journal Articles

An Old Story: Aggressive Antithrombotic Approach Reduced or Increased the Risk of Destabilization and Adverse Events: More Questions Than Answers.

Giorgio Corinaldesi, MD, PhD, Christian Corinaldesi, MD

Blood (2009) 114 (22): 4185.

https://doi.org/10.1182/blood.V114.22.4185.4185

Published: 2009

Journal Articles

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Anaadriana Zakarija, MD, Thanh Ha Luu, Hau C. Kwaan, MD, PhD, June McKoy, MD, JD, MPH, Ivy Weiss, BS, Paul Yarnold, Nicholas Bandarenko, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 892.

https://doi.org/10.1182/blood.V114.22.892.892

Published: 2009

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

Journal Articles

Efficacy and Safety of Primary Antithrombotic Prophylaxis with Ticlopidine and with Aspirin In Patients with Essential Thrombocythemia and Polycythemia Vera. Results from a Cohort Study.

Marco Ruggeri, Alberto Tosetto, Irene Bolgan, Francesco Rodeghiero

Blood (2008) 112 (11): 1743.

https://doi.org/10.1182/blood.V112.11.1743.1743

Published: 2008

Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3339.

https://doi.org/10.1182/blood.V110.11.3339.3339

Published: 2007

Journal Articles

Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes.

Vaishali V. Saste, MD, Deirdra R. Terrell, MPH, Sara K. Vesely, PhD, James N. George, MD

Blood (2007) 110 (11): 1315.

https://doi.org/10.1182/blood.V110.11.1315.1315

Published: 2007

Journal Articles

Identification of Trigger Factors Initiating an Acute TTP Episode in 68 Patients.

Charis von Auer, MD, Andreas Wilken, MD, Inge Scharrer

Blood (2007) 110 (11): 3969.

https://doi.org/10.1182/blood.V110.11.3969.3969

Published: 2007

Journal Articles

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Charles L. Bennett, MD, PhD, MPP, Thanh Ha Luu, BA, Anaadriana Zakarija, MD, Hau C. Kwaan, MD, PhD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, John F. Cursio, MS, June M. McKoy, MD, JD, MPH, Charlie Buffie, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD, Ravindra Sarode, MD, X. Long Zheng, MD, PhD, Thomas J. Raife, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Gail A. Rock, MD, PhD

Blood (2007) 110 (11): 2088.

https://doi.org/10.1182/blood.V110.11.2088.2088

Published: 2007

Journal Articles

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Elizabeth A. Richey, BA, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, MD, PhD, Anaadriana Zakarija, MD, MSCI, Nicholas Banderanko, MD, Dilip K. Pandey, MD, PhD, June M. McKoy, MD, JD, MPH, Paul R. Yarnold, PhD, Dennis W. Raisch, PhD, Jeffrey L. Winters, MD, Thomas J. Raife, MD, John F. Cursio, MS, Matthew J. Fisher, Thomas L. Ortel, MD, PhD, Martin S. Tallman, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Joel L. Moake, MD

Blood (2007) 110 (11): 2089.

https://doi.org/10.1182/blood.V110.11.2089.2089

Published: 2007

Journal Articles

Long-Term Evaluation of 205 Patients with Essential Thrombocythemia: Clinical Outcome, Efficacy and Safety with Respect to Different Therapies.

Nicola Vianelli, MD, Antonio deVivo, MD, Mauro Fiacchini, MD, Alessandro Lucchesi, MD, Benedetta Giannini, MD, Michele Baccarani, MD

Blood (2005) 106 (11): 4941.

https://doi.org/10.1182/blood.V106.11.4941.4941

Published: 2005

NARROW

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Pharmacokinetics, Pharmacodynamics and Safety of Ticagrelor in Children with Sickle Cell Disease: Results of a Two-Part Phase 2 Study

Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies

The Alternate Complement Pathway in Thrombotic Thrombocytopenic Purpura

Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.

Essential Thrombocythaemia in Young Adults: Clinical Characteristics and Outcomes – a Single Center Experience

Anti-ADAMTS13 Inhibitor Boosting During Plasma Exchange Therapy Often Causes an Intractable Acquired Idiopathic TTP

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty Year Review

Translating Research Into Policy: A Review of Pharmacovigilance Efforts From the Southern Network On Adverse Reactions (SONAR) Group

Finishing the Picture: Clopidogrel Is Indeed the Most Common Drug Associated with Thrombotic Thrombocytopenic Purpura (TTP) In FDA Databases: Its Mechanism, Laboratory Findings, Clinical Features, and Epidemiology Differ From That Associated with Ticlopidine

An Old Story: Aggressive Antithrombotic Approach Reduced or Increased the Risk of Destabilization and Adverse Events: More Questions Than Answers.

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Efficacy and Safety of Primary Antithrombotic Prophylaxis with Ticlopidine and with Aspirin In Patients with Essential Thrombocythemia and Polycythemia Vera. Results from a Cohort Study.

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes.

Identification of Trigger Factors Initiating an Acute TTP Episode in 68 Patients.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Long-Term Evaluation of 205 Patients with Essential Thrombocythemia: Clinical Outcome, Efficacy and Safety with Respect to Different Therapies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only